WebOct 16, 2024 · As a flow cytometric test, CyPath Lung helps in the diagnosis of lung cancer. Patients can gather sputum samples non-invasively at home through the acapella device. The laboratory can then process the samples. Sample data is gained by flow cytometry, which is a technique that can not only count but also quickly sort and profile individual cells. WebMar 28, 2024 · CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its...
bioAffinity Technologies Announces Precision Pathology Services ...
WebCyPath ® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding. The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung. WebIndustry: Offices and clinics of medical doctors Printer Friendly View Address: 201 ROUTE DE GENAS 69100, VILLEURBANNE, AUVERGNE RHONE ALPES France See other locations Phone: Website: www.cypath.fr Employees (this site): Actual Revenue: Actual Fiscal Year End: Year Started: Incorporated: ESG ranking: ESG industry average: What … tsh ft4 nhg
CyPath™ Lung for Physician
WebCyPath ® Lung is a non-invasive test that assists clinical decision-making for patients whose computed tomography (CT) results in a suspicious finding. CyPath ® Lung test … WebJul 7, 2024 · CYPATH is a private diagnostics group with more than 60 pathologists specialized in Anatomy and Pathological Cytology, associated in SELAS (liberal practice company by simplified action). The group is the result of successive associations of various medical practices located in Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté and … WebAug 12, 2024 · bioAffinity Technologies recently completed a test validation trial of CyPath ® Lung evaluating sputum from people at high risk for lung cancer, including patients with the disease and others who were cancer-free. The trial resulted in 92% sensitivity and 87% specificity in the group of patients who had no or smaller than 2 cm nodules in the lung. tsh ft3 ft4 連月